TRENTON, N.J. (AP) — Generic drug giant Teva formally offered to buy fellow drugmaker Mylan about $40.1 billion in cash and stock on Tuesday, despite Mylan's cold shoulder and the certainty the proposed acquisition will bring intense scrutiny by antitrust regulators. If Israel-based Teva Pharmaceutical Industries Ltd. succeeded, the combination would dominate the global generic drug market, be a major contender in some other specialty drug categories — and have the leverage to try to raise generic drugs prices. On Friday, the Dutch company said anti-trust regulators probably wouldn't approve a deal and said it prefers to remain a stand-alone company and instead buy generic drug and ingredients maker Perrigo Co.